Welcome to CDC Stacks | Meningococcal conjugate vaccines: optimizing global impact - 4006 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Meningococcal conjugate vaccines: optimizing global impact
  • Published Date:
    Sep 21 2011
  • Source:
    Infect Drug Resist. 2011; 4:161-169.
Filetype[PDF - 171.94 KB]


Details:
  • Description:
    Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, avidity, immunologic memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs have been established across the globe. Many of these vaccination programs have resulted in significant decline in meningococcal disease in several countries. Recent introduction of serogroup A conjugate vaccine in Africa offers the potential to eliminate meningococcal disease as a public health problem in Africa. However, the duration of immune response and the development of widespread herd immunity in the population remain important questions for meningococcal vaccine programs. Because of the unique epidemiology of meningococcal disease around the world, the optimal vaccination strategy for long-term disease prevention will vary by country.

  • Document Type:
  • Collection(s):
No Related Documents.
You May Also Like: